News >

Adding Durvalumab to Chemoradiation Improves OS in Unresectable Stage III NSCLC

Kristie L. Kahl
Published: Tuesday, Sep 25, 2018

Scott J. Antonia, MD

Scott J. Antonia, MD

Durvalumab (Imfinzi) induced a clinically meaningful improvement in overall survival (OS) compared with placebo in patients with stage III, unresectable non–small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

“Do these results apply to mutation-driven tumors? Likely, yes,” Vokes added. “And what is the optimal treatment duration? These are all questions that remain.”


  1. Antonia S, Villegas A, Daniel D, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. Presented at: the IASLC 19th World Conference on Lung Cancer; September 23-26, 2018; Toronto, Canada. Abstract PL02.01.
  2. Antonia S, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC [published online ahead of print September 25, 2018]. N Eng J Med. doi: 10.1056/NEJMoa1809697.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication